Clinical trials: Castration-Resistant Prostate Cancer
Solid Tumors, Non-small Cell Lung Cancer
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive…
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03473925
- Testing
- Navarixin, Pembrolizumab
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer Metastatic
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.
- Trial name
- Prospect (NCT01322490)
- Testing
- PROSTVAC-V, PROSTVAC-F, GM-CSF
- Where
- 220 sites in United States, Australia and 14 more
- Volunteers
- 1,297 people
- Sponsor
- Bavarian Nordic